Case report

Myroides cellulitis and bacteremia: A case report

William A. Beathard, Aaron Pickering, Micah Jacobs

University of Pittsburgh Medical Center (UPMC) St. Margaret, 815 Freepost Rd, Pittsburgh, PA, 15215, United States

Introduction

Flavobacterium, a genus of bacterium characterized as gram negative, nonmotile, yellow-pigmented, nonsporulating rods that produce a robust, fruity fragrance on nutrient agar was amended to exclude the reclassified genus Myroides in 1996 [1,2]. Myroides odoratum and odoratinimus are two clinically significant species inclusive of the genus are abundantly present environmentally soil and water samples. These bacterial species were originally isolated in feces from patients suffering from typhoid fever and acute gastroenteritis. Review of the literature demonstrates isolation of Myroides spp. from urine, blood, respiratory secretions and wound samples from a variety of infections ranging from simple urinary tract infection to more severe conditions such as necrotizing fasciitis [3–5]. The pathogenicity of Myroides spp. in human hosts continue to be under documented, however this bacterium's opportunistic nature lends credence to critical infections in immunocompromised patients [3,6–8]. Myroides spp. are acknowledged as having broad, intrinsic antimicrobial resistance profiles and as reported in a single case documenting a M. odoratinimus infection of a recurrent calcaneal ulcer in an immunocompromised host, have the propensity to develop biofilms [2,9,10]. This report documents a case of Myroides bacteremia secondary to a soft tissue infection of the lower extremities susceptible to meropenem and ciprofloxacin from antibiotics that were tested. Medical literature on documented Myroides spp. infections is also reviewed.

Case presentation

An 88-year-old male with a past medical history significant for persistent atrial fibrillation not on chronic anticoagulation, type 2 diabetes mellitus (most recent HbA1c 6.2 % on 6/26/2020), chronic diastolic heart failure, hypertension, hyperlipidemia, chronic kidney disease stage III, coronary artery disease, and chronic lower extremity edema presented with bilateral extremity swelling and redness of unknown duration, left extremity worse than the right. It is noted that the patient has ambulatory dysfunction and suffers from frequent falls, the most recent sustained approximately one week prior to admission. The family reports a one-week duration of ulceration, edema, and redness in bilateral lower extremities, as well as poor adherence with compression garment therapy. The patient was evaluated by his primary care physician 2 days prior to admission and was diagnosed with cellulitis of the right lower extremity. A 5-day course of oral cephalexin 250 mg 4 times daily was prescribed at that time.

Upon presentation to the hospital, the patient was afebrile and initial vital signs were within normal limits with the exception of ECG notable for atrial flutter with variable AV block in the emergency room. Clinically relevant laboratory studies revealed evidence of an acute kidney injury with a blood urea nitrogen (BUN) and serum creatinine (Scr) of 104 mg/dL and 1.97 mg/dL respectively (baseline Scr of ∼1.6 mg/dL). Physical examination revealed significant bilateral lower extremity edema, warmth and erythematous bilateral lower legs involving the feet with multiple areas of scabbing concerning for cellulitis. Onychomycosis was present with notable scaling between the toes with dried blood.

Infectious workup was significant for an elevated lactate of 3.0 mMol/L and a C-reactive protein of 31.0 mg/dL (normal range...
0.0–0.9 mg/dL) in the absence of leukocytosis. The patient was empirically initiated on intravenous vancomycin and received a single 1250 mg dose in the ED in addition to cefepime (1 g every 12 h) for broad-spectrum coverage of cellulitis refractory to oral antibiotics. Blood cultures taken in the ED on hospital day 0 from a peripheral intravenous access site at the right antecubital space grew gram negative rods from the aerobic bottle later speciated by Vitek® 2 system as *Myroides* spp. on day 5 of hospital stay. Growth was confirmed by a second set of blood cultures taken from the right hand obtained on the hospital floor on day 0 also turning positive for *Myroides* spp. on hospital day 5. Susceptibility data revealed multidrug resistance. The isolate demonstrated sensitivity to only ciprofloxacin and meropenem of antibiotics tested (Table 1). Bacterial identification resulted in antimicrobial switch to meropenem 1 g every 8 h on day 4. Leukocytosis clinically peaked on day 7 of admission (12,900 cells/ccm with 66 % neutrophils). Repeat blood cultures were drawn on the floor (on day 4) reflected 5 days of no growth on hospital day 9. Upon clinical resolution of symptoms, the patient was stable for discharge on hospital day 14. The patient was transitioned to oral ciprofloxacin 500 mg twice daily for 6 days at discharge to complete 14 total days of effective antibiotic therapy.

**Discussion**

*Myroides* spp., a genus previously classified as *Flavobacterium*, are opportunistic, environmental, gram negative organisms that while infrequently infecting humans, can cause life threatening infections particularly in immunosuppressed persons. A 2019 case report authored by LaVergne and colleagues chronicles a total of just 60 reported infections caused by *Myroides* spp. as listed in the U.S. National Institutes of Health’s National Library of Medicine [11]. Of the 60-total cases, the paper cites 15 cases involving skin and soft tissue infections with 6 of which progressing to bacteremia. A sample of confirmed *Myroides* spp. skin and soft tissues infections illuminates prominent clinical similarities to the present case with respect to the course of infection and multidrug resistance.

A review of the 6 infections involving bacteremia and a report documented after LaVergne’s paper demonstrated patients with ages ranging from 49 to 74 years of age, of which 4 were noted to have immunocompromising underlying conditions [3,11–17]. Of importance, with the exception of diet-controlled type 2 diabetes mellitus (most recent HbA1c 6.2 % on 6/26/2020, HbA1c < 7% for past 4 years), the present case occurred in a patient devoid of major immunocompromising conditions such as malignancy or chronic steroid use. The patient’s advanced age of 88 may have been a contributing immunocompromising condition and led to some degree of immunosuppression. Cases of *Myroides* spp. infections in immunocompetent persons are uncommon, with the literature only providing three additional examples [4,5,13]. This case of *Myroides* spp. infection adds additional material to the literature for reports in immunocompetent patients, a rare occurrence in an already uncommon infection. Empiric broad spectrum antimicrobials were initiated in three of the cases in the context of severe cellulitis. Of those not started on broad spectrum antibiotics, two cases reported initiation of cefazolin secondary to targeted cellulitis coverage while the remainder were initiated on ceftriaxone and amoxicillin/clavulanic acid with similar intent [12,13,16,17]. Following isolation and confirmed growth of *Myroides* spp. from blood cultures, sensitivity testing reflected global multidrug resistance. Isolated strains demonstrated susceptibility to fluoroquinolones, carbapenems, trimethoprim-sulfamethoxazole, higher generation cephalosporin and penicillin antibiotics. All strains were resistant to aminoglycosides. This historical resistance pattern was well documented by Holmes et al. and mirrored by the current case of which the strain was only sensitive to meropenem and ciprofloxacin of the tested antibiotics [2].

The mechanisms through which *Myroides* spp. retain their resistance to numerous antimicrobials agents with a diverse array of pharmacological activities remains poorly understood. Hu et al. synthesizes preliminary opinions gathered on the hypothesized mechanisms of *Myroides* spp. pan-resistance. It was suggested that *M. odoratum* and *M. odoratinimus* demonstrate resistance to β-lactam secondary to TUS-1 and MUS-1, chromosome-encoded β-lactamases [18]. In contrast, aminoglycoside and carbapenem resistance was also studied and considered to be plasmid-mediated, citing an instance of a Klebsiella pneumoniae carbapenemase (KPC) gene discovered within a *Myroides* strain. Furthermore, a more recent study by the same author predicted virulence factors present in both environmental and pathogenic strains of *M. odoratinimus* isolates. Based on the presence of *bauE* (ferric siderophore binding protein paralleled in Acinetobacter baumanii), capsular LPS (complement inhibitor found in both gram-negative and gram-positive that prevents expulsion by host cells), intracellular survival factors *katA*, *clpF*, EF-Tu, and *sodB*, as well as bacterial DnaK (heat-shock protein involved in cellular host attachment) found within experimental strains, Hu et al. posited that the analogous presence of these genes are what allow virulence and antibiotic resistance to gain purchase [5]. While not definitive, these mechanistic and pathogenetic models provide valuable insight into understanding the intrinsic resistance of these as well as prospective avenues for methods to circumvent the resistance of these rare and clinically challenging infections.

**Conclusion**

Infections secondary to the exceptionally enigmatic *Myroides* spp. remain poorly understood. The predisposition of and poor
outcomes related to immunocompromised patients advance the
necessity of exploring mechanisms for resistance as well as
analogous virulence factors. This organism's multidrug resistance
and infrequently confirmed presence in clinical settings speak to
the need for further study and the dependence of infectious
disease providers on well documented cases.

Declaration of Competing Interest

The author declares that there is no conflict of interest
regarding the publication of this case study.

Funding

This research did not receive any specific grant from funding
agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

William A. Beatham: Writing - original draft, Writing - review
& editing. Aaron Pickering: Supervision, Writing - review & editing. Micah Jacobs: Conceptualization, Writing - review & editing.

Acknowledgments

I would like to acknowledge Dr. Aaron Pickering, PharmD, BCPS
and Dr. Micah Jacobs, MD for their generous contributions to this
case study including their assistance in the research process,
manuscript editing, language crafting, and overall guidance.

References

[1] Vancanneyt M, Segers P, Torck U, et al. Reclassification of Flavobacterium
odoratum(Stutzer 1929) strains to a new genus, Myroides, as Myroides
odoratuscomb. Nov. And Myroides odoratimus sp nov. Int J Syst Bacteriol
1996;46:926–32.
[2] Holmes B, Snell JJ, Lapage SP.Flavobacterium odoratum: a species resistant to a
wide range of antimicrobial agents. J Clin Pathol 1979;32:73–7.
[3] Beharrysingh R. Myroides bacteremia: a case report and concise review. ID
Cases 2017;8:34–6. doi:http://dx.doi.org/10.1016/j.idcr.2017.02.012 Published
2017 Feb 28.
[4] Maraki S, Sarchianaki E, Barbagadakis S. Myroides odoratimus soft tissue
infection in an immunocompetent child following a pig bite: case report and
literature review. Braz J Infect Dis 2012;16(4):390–2. doi:http://dx.doi.org/
10.1016/j.bjid.2012.06.004.
[5] Benedetti F, Rassu M, Pavan G, Sefton A, Pellizzer G. Septic shock, pneumonia,
and soft tissue infection due to Myroides odoratimus: report of a case and
review of Myroides infections. Infection 2011;39(2):161–5. doi:http://dx.doi.
org/10.1007/s15010-010-0077-7.
[6] Licker M, Sorescu T, Rus M, et al. Extensively drug-resistant Myroides
odoratimus - a case series of urinary tract infections in
immunocompromised patients. Infect Drug Resist 2018;11:743–9. doi:
http://dx.doi.org/10.2147/IDR.S151069 Published 2018 May 18.
[7] Lorenzin G, Piccinnelli G, Carlassara L, et al. Myroides odoratimus urinary tract
infection in an immunocompromised patient: an emerging multidrug-
resistant micro-organism. Antimicrob Resist Infect Control 2018;7:96. doi:
http://dx.doi.org/10.1186/s13756-018-0391-4 Published 2018 Aug 6.
[8] Spanik S, Trupl J, Krčmer V. Nosocomial catheter-associated Flavobacterium
odoratum bacteremia in cancer patients. J Med Microbiol 1998;47(2):183,
doi:http://dx.doi.org/10.1099/00222615-47-2-183.
[9] Hu S, Cao L, Wu Y, et al. Comparative genomic analysis of Myroides
odoratimus isolates. MicrobiolZoenopen 2019;8(2):e00634. doi:http://dx.doi.
org/10.1002/mbo3.634.
[10] Pompilio A, Galardi G, Gherardi G, et al. Infection of recurrent calcaneal ulcer
caused by a biofilm-producer Myroides odoratimus strain. Folia Microbiol
(Praha) 2018;63(2):203–7. doi:http://dx.doi.org/10.1007/s12223-017-0552-5.
[11] LaVeigne S, Gauffin T, Richman D. Myroides injenensis bacteremia and severe
cellulitis. Open Forum Infect Dis 2019;6(7). doi:http://dx.doi.org/10.1093/ofid/
ofz282 ofz282. Published 2019 Jun 17.
[12] Meyer A, Dang H, Roland W. Myroides spp. Cellulitis and bacteremia: a case
report. IDCases 2019;18:e00638. doi:http://dx.doi.org/10.1016/j.idcr.2019.
e00638 Published 2019 Sep 7.
[13] Green BT, Green K, Nolan PE. Myroides odoratus cellulitis and bacteremia: case
report and review. Scand J Infect Dis 2001;33(12):932–4. doi:
http://dx.doi.org/10.1080/03039920110036554013.00765.
[14] Mofwani Bharat MD, Krezolek Dorota MD, Symeonides Simon MD, Khayr
Walid MD. Myroides odoratum Cellulitis and Bacteremia: A Case Report. Infect
Dis Clin Pract 2004;12(November 6):343–4. doi:http://dx.doi.org/10.1097/01.
clp.0000144904.51074.79.
[15] Hsueh PR, Wu JJ, Hsueh TR, Hsieh WC. Bacteremic necrotizing fasciitis due to
Flavobacterium odoratum. Clin Infect Dis 1995;21(5):1337–8. doi:
http://dx.doi.org/10.1093/cid/21.5.1337.
[16] Bachmeyer C, Entessengle H, Kho射手rani K, et al. Cellulitis due to Myroides
odoratimus in a patient with alcoholic cirrhosis. Clin Exp Dermatol 2008;33
(1):97–8. doi:http://dx.doi.org/10.1111/j.1365-2230.2007.02590.x.
[17] Bachmeyer C, Entessengle H, Kho射手rani K, et al. Cellulitis due to Myroides
odoratimus in a patient with alcoholic cirrhosis. Clin Exp Dermatol 2008;33
(1):97–8. doi:http://dx.doi.org/10.1111/j.1365-2230.2007.02590.x.
[18] Hu SH, Yuan SX, Qu H, et al. Antibiotic resistance mechanisms of Myroides sp. J
Zhejiang Univ Sci B 2016;17(3):188–99. doi:http://dx.doi.org/10.1631/jzus.
B1500068.